Evaluation of mean platelet volume before and after cyclophosphamide treatment in systemic sclerosis associated interstitial lung disease



Cyclophosphamide, Mean platelet volume, Systemic Sclerosis


Aim: Studies carried out in patients with systemic sclerosis (SSc) have shown that mean platelet volume (MPV) is associated with more advanced stage of SSc. However, the effect of cyclophosphamide (CP) on MPV in systemic sclerosis-associated interstitial lung disease (SSc-ILD) is less clear. In this study, we aimed to investigate the MPV response to CP treatment in SSc-ILD. Methods: Thirty-eight SSc-ILD patients who responded positively to CP were included in this retrospective cohort study. MPV values before the treatment were compared with third, sixth, and ninth months’ values during treatment. Results: Over the nine-year period, 82 patients were diagnosed with SSc in the rheumatology clinic of our hospital. Forty-three of them had SSc-ILD and all were administered CP treatment for 9 months. Thirty-eight clinically benefited from CP, among which 32 were females (84%) and 6 (16%) were males. The MPV levels in SSc-ILD patients after CP (9.44 fL) were significantly higher than those before CP (7.89 fL) (P=0.001). Conclusion: Cyclophosphamide treatment causes an increase in MPV in SSc-ILD. MPV, a negative acute phase reactant, is considered an independent risk factor for coronary and peripheral artery diseases. Patients receiving CP should be followed more closely for such diseases.


Download data is not yet available.


Cappelli S, Bellando Randone S, Camiciottoli G, De Paulis A, Guiducci S, Matucci-Cerinic M. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev. 2015;24(137):411-9.

Gear AR, Camerini D. Platelet chemokines and chemokine receptors: Linking hemostasis, inflammation, and host defense. Microcirculation. 2003;10:335–50.

Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. Thromand Hematol. 2003;1:1897-905.

Friedhoff LT, Seibold JR, Kim HC, Simester KS. Serotonin induced platelet aggregation in systemic sclerosis. Clin and Exp Rheu. 1984;2:119-23.

Postlethwaite AE, Chiang TM. Platelet contributions to the pathogenesis of systemic sclerosis. Cur Opin in Rhe. 2007;19:574-9.

Giraud B, Hebert G, Deroussent A, Veal GJ, Vassal G, Paci A.Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opin Drug Metab Toxicol. 2010;6(8):919-38.

Eren R, Doğu MH, Koç A, Altındal Ş, Yokuş O, Suyanı E. The association of mean platelet volume and platecrit and bone marrow fibrosis in patients with essential thrombocythemia: A cohort study. J Surg Med. 2019;3(2):176-9.

İnanır M. An investigation of platelet parameters in smoking patients with coronary slow flow detected during coronary angiography. J Surg Med. 2020;4(4):281-4.

Abanoz M. Predictive value of plateletcrit in the diagnosis of lower extremity deep vein thrombosis. J Surg Med. 2020;4(2):148-51.

Bıyık İ, Aslan MM, Keskin F. Association between platelet indices and missed abortion. J Surg Med. 2019;3(8):549-52.

Aksoy S, Kilickap S, Hayran M, Harputluoglu H, Koca E, Dede DS. Platelet size has diagnostic predictive value for bone marrow metastasis in patients with solid tumors. Int J Lab Hematol. 2008;30:214-9.

Korniluk A, Koper-Lenkiewicz OM, Kamińska J, Kemona H, Dymicka-Piekarska V. Mean platelet volume (MPV): new perspectives for an old marker in the course and prognosis of inflammatory conditions. Mediators of Inflammation. 2019;2019:14.

Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17:47-58.

Balbaloglu O, Korkmaz M, Yolcu S, Karaaslan F, Beceren NG. Evaluation of mean platelet volume (MPV) levels in patients with synovitis associated with knee osteoarthritis. Platelets. 2014;25(2):81-5.

Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint, Bone, Spine. 2008;75:291-4.

Gasparyan AY, Sandoo A, Stavropoulos-Kalinoglou A, Kitas GD. Mean platelet volume in patients with rheumatoid arthritis: The effect of anti-TNF-α treatment. Rheumatology International. 2010;30:1125-9.

Sahin A, Yetisgin A, Sahin M, Durmaz Y, Cengiz AK. Can Mean Platelet Volume be a Surrogate Marker of Inflammation in Rheumatic Diseases? West Indian Med J. 2015;65:165-9.

Soydinc S, Turkbeyler IH, Pehlivan Y, Soylu G, Goktepe MF, Bilici M et al. Mean Platelet Volume Seems To Be a Valuable Marker in Patients with Systemic Sclerosis Inflammation. 2014;37(1):100-6.






Research Article

How to Cite

Atilla N, Yıldırım Çetin G. Evaluation of mean platelet volume before and after cyclophosphamide treatment in systemic sclerosis associated interstitial lung disease. J Surg Med [Internet]. 2020 Aug. 1 [cited 2024 May 25];4(8):682-4. Available from: https://jsurgmed.com/article/view/736242